Welcome to our dedicated page for Immatics N.V news (Ticker: IMTX), a resource for investors and traders seeking the latest updates and insights on Immatics N.V stock.
Immatics N.V. develops clinical-stage cancer immunotherapies built around T-cell receptor biology, with a stated focus on precision targeting of PRAME across solid tumors. News about IMTX most often covers clinical updates for PRAME-directed cell therapies and TCR bispecifics, including anzu-cel (anzutresgene autoleucel, IMA203), IMA203CD8, IMA402 and IMA401 MAGEA4/8. Company announcements also cover presentations at oncology meetings such as ASCO, AACR and ESMO, where Immatics reports safety, dose-escalation and anti-tumor activity data across melanoma, ovarian cancer, synovial sarcoma and other PRAME-positive cancers.
Recurring updates include financial results, business updates, collaboration activity, clinical and regulatory disclosures, leadership changes, shareholder voting matters and capital-structure disclosures for the Nasdaq-listed biotechnology company.
Immatics (NASDAQ: IMTX) reported extended Phase 1b data for its PRAME TCR T-cell therapy anzu-cel (IMA203) in heavily pretreated metastatic melanoma at the 2026 ASCO meeting.
At the RP2D, anzu-cel showed a 56% confirmed ORR, 14.6-month mDOR, 6.1-month mPFS, 16.2-month mOS and a predictable, manageable safety profile, supporting the ongoing SUPRAME Phase 3 trial and a planned BLA submission in 1H 2027.
Immatics (NASDAQ:IMTX) reported Phase 1 data for IMA401, a MAGEA4/8 TCR bispecific, in heavily pretreated solid tumors. At the recommended Phase 2 dose, IMA401 with or without pembrolizumab showed a 29% confirmed ORR and 64% DCR in head and neck cancer, with 8.8-month mDOR.
Melanoma patients achieved 33% cORR and 67% DCR, with responses lasting over six months. Safety showed mostly low-grade CRS, lymphopenia and neutropenia, with no ICANS observed. These data support an ongoing Phase 1 IMA401/IMA402 combination cohort in sqNSCLC, with first data expected in 2027.
Immatics (NASDAQ:IMTX) reported updated Phase 1 data for its PRAME-targeting TCR T-cell therapy IMA203CD8 in gynecologic cancers and synovial sarcoma at ASCO 2026.
In clinically relevant gynecologic cohorts, ORR was 63% with 50% confirmed, including four complete responses. In synovial sarcoma, ORR was 67%, confirmed ORR 64%, with durable responses up to ~3 years. IMA203CD8 showed a manageable safety profile without treatment-related Grade 5 events, and Immatics expects to define the recommended Phase 2 dose (RP2D) in 2026 and present further data in the second half of 2026.
Immatics (NASDAQ: IMTX) reported Q1 2026 results and a broad PRAME-focused clinical pipeline update. Cash, cash equivalents and other financial assets were $521.5 million as of March 31, 2026, with cash reach projected into 2028.
Key 2026 milestones include Phase 3 SUPRAME interim/final analyses for anzu-cel in advanced melanoma, multiple PRAME cell therapy and bispecific data readouts, and progress toward a planned 2027 BLA filing and first commercial launch.
Immatics (NASDAQ: IMTX) announced four oral presentations at the 2026 ASCO Annual Meeting (May 29–June 2, 2026) featuring updated Phase 1/1b clinical data for PRAME-directed cell therapies anzucel (IMA203), IMA203CD8 (GEN2), PRAME TCR therapies in synovial sarcoma, and first-in-human IMA401 bispecific results.
Abstracts will be available on May 21, 2026 at 5:00 pm ET; sessions occur May 30–June 1 in Chicago, IL.
Immatics (NASDAQ: IMTX) reported a late-breaking AACR 2026 poster of an individual pediatric case showing deep, durable remission after treatment with a PRAME-directed TCR T-cell therapy.
A 17-year-old with metastatic PRAME-positive nephroblastoma (16 cm abdominal lesion; lung, liver, brain mets) achieved radiologic and molecular remission with response ongoing at 6 months; cytokine release syndrome was manageable and resolved.
Immatics (NASDAQ: IMTX) reported full-year 2025 results and a business update on March 5, 2026, highlighting clinical progress across its PRAME franchise and financials. Cash and other financial assets totaled $551.4 million as of December 31, 2025, with cash reach extended into 2028.
Key clinical timelines include SUPRAME Phase 3 interim and final analyses expected in 2026, BLA submission in 1H 2027, and commercial launch in 2H 2027. The company completed a $125 million public offering on December 8, 2025.
Immatics (NASDAQ: IMTX) announced updated Phase 1a dose‑escalation data for its second‑generation PRAME cell therapy IMA203CD8 on December 11, 2025. Key results at a low median infused dose of 1.6×10⁹ TCR T cells (range 0.4–12.5×10⁹): a confirmed objective response rate (cORR) 36% (23/64), ORR 46% (32/69), tumor reduction in 78% (54/69), disease control rate 84% (58/69) at week 6, and median duration of response 9.2 months with median follow‑up of 14 months. Tolerability was manageable across dose levels; CRS was mostly Grade 1–2 (Grade 3: 9%, Grade 4: 1%) and no Grade 5 events linked to IMA203CD8. A dose‑dependent signal in ovarian carcinoma (n=11) included confirmed responses and a metabolic complete response at the highest ovarian dose (7.1×10⁹). Dose escalation is ongoing (dose level 7) and Immatics plans to determine RP2D in 2026.
Immatics (NASDAQ: IMTX) agreed to sell 12,500,000 ordinary shares at $10.00 per share in an underwritten offering, generating expected gross proceeds of $125 million before underwriting discounts and offering expenses.
The offering is expected to close on December 8, 2025, subject to customary closing conditions; a registration statement was declared effective on April 3, 2025. Jefferies, Leerink Partners and Cantor are joint book‑running managers. The shares are being offered only by prospectus supplement and accompanying prospectus.
Immatics (NASDAQ: IMTX) reported Q3 2025 results and a business update on November 17, 2025, highlighting clinical progress across its PRAME franchise and a cash position of $505.8M as of September 30, 2025.
Key clinical highlights: anzu-cel (IMA203) Phase 3 SUPRAME trial ongoing with interim and final PFS analyses expected in 2026, planned BLA submission in 1H 2027 and potential launch in 2H 2027. Phase 1b uveal melanoma update (n=16): cORR 67%, mDOR 11.0 months, mPFS 8.5 months, mOS not reached at 14.3 months. IMA203CD8 GEN2 dose escalation updates planned for Dec 11, 2025.
Bispecifics: IMA402 PRAME showed RP2D-range cORR 30% (6/20) with ongoing Phase 1b expansions in 2026; IMA401 MAGEA4/8 demonstrated clinical proof-of-concept with activity in multiple indications. Q3 financials: revenue $6.1M, R&D $55.4M, net loss $59.3M.